Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 6/20 | 0.45 |
| ▸ | SLC6A4 | P31645 | 5/20 | 0.45 |
| ▸ | SLC6A3 | Q01959 | 4/20 | 0.45 |
| ▸ | HTR1A | P08908 | 2/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | MLNR | O43193 | 1/20 | 0.43 |
| ▸ | CACNA1F | O60840 | 1/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.43 |
| ▸ | DRD2 | P14416 | 1/20 | 0.43 |
| ▸ | KCNE1 | P15382 | 1/20 | 0.43 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.43 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.43 |
| ▸ | HTR2A | P28223 | 1/20 | 0.43 |
| ▸ | HTR2C | P28335 | 1/20 | 0.43 |
| ▸ | MC4R | P32245 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29974633 | 1.00 | SLC6A2 (0.45) | SLC6A2SLC6A4SLC6A3HTR1AKMT2A | |
| SCHEMBL21742925 | 1.00 | SLC6A2 (0.45) | SLC6A2SLC6A4SLC6A3HTR1AKMT2A | |
| SCHEMBL21731326 | 1.00 | SLC6A2 (0.45) | SLC6A2SLC6A4SLC6A3HTR1AKMT2A | |
| SCHEMBL29447472 | 1.00 | SLC6A2 (0.45) | SLC6A2SLC6A4SLC6A3HTR1AKMT2A | |
| SCHEMBL23958019 | 0.84 | SLC6A2 (0.35) | SLC6A2SLC6A4SLC6A3HTR1AKMT2A | |
| SCHEMBL4590329 | 0.84 | SLC6A2 (0.64) | SLC6A2SLC6A4SLC6A3HTR1AKMT2A | |
| SCHEMBL24297817 | 0.81 | HTR1A (0.52) | SLC6A2SLC6A4SLC6A3HTR1AKMT2A | |
| SCHEMBL21722767 | 0.80 | SLC6A2 (0.66) | SLC6A2SLC6A4SLC6A3HTR1AKMT2A | |
| SCHEMBL23521672 | 0.80 | SLC6A2 (0.66) | SLC6A2SLC6A4SLC6A3HTR1AKMT2A | |
| SCHEMBL21722768 | 0.80 | SLC6A2 (0.66) | SLC6A2SLC6A4SLC6A3HTR1AKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12570643-B2 | 3-aryloxy-3-five-membered heteroaryl propylamine compound, and crystal form and use thereof | SHANGHAI LEADO PHARMATECH CO. LTD. (CN) | 2026-03-10 | — | — | US | disclosed |
| EP-3838900-B1 | 3-ARYLOXY-3-ARYL-PROPYLAMINE COMPOUND AND USES THEREOF | ZHANGZHOU PIEN TZE HUANG PHARM (CN) | 2025-02-12 | — | — | EP | disclosed |
| US-20250042884-A1 | 3-ARYLOXYL-3-FIVE-MEMBERED HETEROARYL PROPYLAMINE COMPOUND AND USE THEREOF | SHANGHAI LEADO PHARMATECH CO. LTD. (CN) | 2025-02-06 | — | — | US | disclosed |
| US-12139476-B2 | 3-aryloxyl-3-five-membered heteroaryl propylamine compound and use thereof | SHANGHAI LEADO PHARMATECH CO. LTD. (CN) | 2024-11-12 | — | — | US | disclosed |
| CN-115135644-B | Preparation method and crystal form of 3-aryloxy-3-five-membered heteroaryl-propylamine compound | 漳州片仔癀药业股份有限公司 | 2024-06-18 | — | — | CN | disclosed |
| CN-114206859-B | 3-Aryloxy-3-five-membered heteroaryl-propylamine compound, and crystal forms and application thereof | 上海璃道医药科技有限公司 | 2024-05-28 | — | — | CN | disclosed |
| CN-112654616-B | 3-aryloxy-3-aryl-propylamines and application thereof | 漳州片仔癀药业股份有限公司 | 2024-03-12 | — | — | CN | disclosed |
| US-20230339920-A1 | PREPARATION METHOD FOR AND CRYSTAL FORM OF 3-ARYLOXY-3-FIVE-MEMBERED HETEROARYLPROPYLAMINE COMPOUND | ZHANGZHOU PIEN TZE HUANG PHARMACEUTICAL CO., LTD. (CN) | 2023-10-26 | — | — | US | disclosed |
| CN-112566909-B | 3-aryloxy-3-five-membered heteroaryl-propylamine compound and application thereof | 上海璃道医药科技有限公司 | 2023-01-03 | — | — | CN | disclosed |
| CN-115135644-A | Preparation method and crystal form of 3-aryloxy-3-pentabasic heteroaryl-propylamine compound | 漳州片仔癀药业股份有限公司 | 2022-09-30 | — | — | CN | disclosed |
| WO-2021160134-A1 | PREPARATION METHOD FOR AND CRYSTAL FORM OF 3-ARYLOXY-3-FIVE-MEMBERED HETEROARYL-PROPYLAMINE COMPOUND | 漳州片仔癀药业股份有限公司 | 2021-08-19 | — | — | WO | disclosed |
| EP-3838899-A1 | 3-ARYLOXYL-3-FIVE-MEMBERED HETEROARYL PROPYLAMINE COMPOUND AND USE THEREOF | Shanghai Leado Pharmatech Co. Ltd. (CN) | 2021-06-23 | — | — | EP | disclosed |
| EP-3838899-A1 | 3-ARYLOXYL-3-FIVE-MEMBERED HETEROARYL PROPYLAMINE COMPOUND AND USE THEREOF | Shanghai Leado Pharmatech Co. Ltd. (CN) | 2021-06-23 | — | — | EP | disclosed |
| EP-3838900-A1 | 3-ARYLOXY-3-ARYL-PROPYLAMINE COMPOUND AND USES THEREOF | Zhangzhou Pien Tze Huang Pharmaceutical Co., Ltd (CN) | 2021-06-23 | — | — | EP | disclosed |
| CN-112654616-A | 3-aryloxy-3-aryl-propylamine compounds and application thereof | 漳州片仔癀药业股份有限公司 | 2021-04-13 | — | — | CN | disclosed |
| CN-112566909-A | 3-aryloxy-3-five-membered heteroaryl-propylamine compound and application thereof | 上海璃道医药科技有限公司 | 2021-03-26 | — | — | CN | disclosed |
| WO-2020228789-A1 | 3-ARYLOXYL-3-FIVE-MEMBERED HETEROARYL PROPYLAMINE COMPOUND, AND CRYSTAL FORM AND USE THEREOF | 上海璃道医药科技有限公司 | 2020-11-19 | — | — | WO | disclosed |
| WO-2020228789-A1 | 3-ARYLOXYL-3-FIVE-MEMBERED HETEROARYL PROPYLAMINE COMPOUND, AND CRYSTAL FORM AND USE THEREOF | 上海璃道医药科技有限公司 | 2020-11-19 | — | — | WO | disclosed |
| CN-111943943-A | 3-aryloxy-3-pentabasic heteroaryl-propylamine compound and crystal form and application thereof | 上海璃道医药科技有限公司 | 2020-11-17 | — | — | CN | disclosed |
| WO-2020035040-A1 | 3-ARYLOXYL-3-FIVE-MEMBERED HETEROARYL PROPYLAMINE COMPOUND AND USE THEREOF | 上海璃道医药科技有限公司 | 2020-02-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12139476-B2 | 3-aryloxyl-3-five-membered heteroaryl propylamine compound and use thereof | TRPV1, TRPA1, TRPM5 | SLC6A2 238/4885SLC6A4 137/4885SLC6A3 55/4885 |
| US-20230339920-A1 | PREPARATION METHOD FOR AND CRYSTAL FORM OF 3-ARYLOXY-3-FIVE-MEMBERED HETEROARYLPROPYLAMINE COMPOUND | TRPV1, TRPC7, TRPC4 | SLC6A2 485/4885SLC6A4 94/4885SLC6A3 177/4885 |
| US-12570643-B2 | 3-aryloxy-3-five-membered heteroaryl propylamine compound, and crystal form and use thereof | TRPA1, TRPM7, TRPV1 | SLC6A2 430/4885SLC6A4 299/4885SLC6A3 226/4885 |
| US-20250042884-A1 | 3-ARYLOXYL-3-FIVE-MEMBERED HETEROARYL PROPYLAMINE COMPOUND AND USE THEREOF | TRPV1, TRPA1, TRPM5 | SLC6A2 238/4885SLC6A4 137/4885SLC6A3 55/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.